Triesence Approval History
- FDA approved: Yes (First approved November 29th, 2007)
- Brand name: Triesence
- Generic name: triamcinolone acetonide
- Dosage form: Injectable Suspension
- Company: Alcon, Inc.
- Treatment for: Temporal Arteritis, Uveitis
Triesence (triamcinolone acetonide) is a synthetic corticosteroid indicated for visualization during vitrectomy and treatment of sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids.
Development History and FDA Approval Process for Triesence
|Dec 3, 2007||Alcon Receives FDA Approval of Triesence Injectable Triamcinolone Suspension for Use in Eye Surgery|
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.